Inhibitory effect of a CD4-CDR3 peptide analog on graft-versus-host disease across a major histocompatibility complex-haploidentical barrier

Blood

Volumn 88, Issue 8, 1996, Pages 3038-3047

  Townsend, Robert M ^b   Briggs, Constance ^b   Marini, Joseph C ^b   Murphy, George F ^b   Korngold, Robert ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD4 ANTIGEN DERIVATIVE; PEPTIDE; PROLINE GLYCINE PROLINE PEPTIDE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALLOIMMUNITY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029973961     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.8.3038.bloodjournal8883038     Document Type: Article

References (47)

1. Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Cambridge, MA, Blackwell Scientific, 1994
2. Graft-vs.-Host Disease. Immunology Pathophysiology, and Treatment. New York, NY, Marcel Dekker, Inc, 1990
3. Poynton CH: T cell depletion in bone marrow transplantation. Bone Marrow Transplant 3:265, 1988
4. Marmont AA, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991
5. Kernan NA: T-cell depletion for prevention of graft-versus-host disease, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Cambridge, MA, Blackwell Scientific, 1994, p 124
6. Doyle C, Strominger JL: Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 330:256, 1987
7. Gay D, Maddon P, Sekaly R, Talle MA, Godfrey M, Long E, Goldstein G, Chess L, Axel R, Kappler J, Marrack P: Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature 328:626, 1987
8. Konig R, Huang L-Y, Germain RN: MHC class II interaction with CD4 mediated by a region analogous to the MHC class binding site for CD8. Nature 356:796, 1992
9. lck. Cell 55:301, 1988
10. lck) that phophorylates the CD3 complex. Proc Natl Acad Sci USA 86:3277, 1989
11. lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell 60:755, 1990
12. Korngold R, Sprent J: Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol 135:3004, 1985
13. Sprent J, Schaefer M, Lo D, Korngold R: Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med 163:998, 1986
14. Korngold R, Sprent J: Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 165:1552, 1987
15. Hamilton BL: L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol 139:2511, 1987
16. Cobbold S, Martin G, Waldmann H: Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation 42:239, 1986
17. Knulst AC, Tibbe GJ, Noort WA, Bril-Bazuin C, Benner R, Savelkoul HF: Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression. Bone Marrow Transplant 13:293, 1994
18. Reinecke K, Mysliwietz J, Thierfelder S: Single as well as pairs of synergistic anti-CD4+ CD8 antibodies prevent graft-versus-host disease in fully mismatched mice. Transplantation 57:458, 1995
19. Hafler DA, Ritz J, Schlossman SF, Weiner HL: Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol 141:131, 1988
20. Racadot E, Rumbach L, Bataillard M, Galmiche J, Henlin J-L, Truttmann M, Herve P, Wijdenes J: Treatment of multiple sclerosis with anti-CD4 monoclonal antibody: A preliminary report on B-F5 in 21 patients. J Autoimmunity 6:771, 1993
21. Lindsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L: Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 36:183, 1994
22. McDonnell JM, Vamum JM, Mayo KH, Jameson BA: Rational design of a peptide analog of the L3T4 CDR3-like region. Immunomethods 1:33, 1992
23. Jameson BA, McDonnell JM, Marini JC, Korngold R: A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 368:744, 1994
24. McDonnell JM, Blank KJ, Rao PE, Jameson BA: Direct involvement of the CDR3-like domain of CD4 in T helper cell activation. J Immunol 149:1626, 1992
25. Bruce J, Symington FW, McKearn TJ, Sprent J: A monoclonal antibody discriminating between subsets of T and B cells. J Immunol 127:2496, 1981
26. Sarmiento M, Glasebrook AL, Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt-2 antigen block T-cell mediated cytolysis in the absence of complement. J Immunol 125:2665, 1980
27. Gillis S, Ferm MM, Ou W, Smith KA: T cell growth factor: Parameters of production and a quantitative microassay for activity. J Immunol 120:2027, 1978
28. Korngold R, Bennink JR: Collection of mouse thoracic duct lymphocytes. Methods Enzymol 108:270, 1984
29. Boussiotis VA, Freeman GJ, Lee BY, Gribben JG, Nadler LM: Induction of T cell clonal anergy results in upregulation of anti-apoptosis survival proteins and absence of fas expression. Blood 86:622a, 1995 (abstr, suppl 1)
30. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE: Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540, 1994
31. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155:585, 1995
32. 1. J Immunol 146:3012, 1991
33. 1. J Immunol 147:1792, 1991
34. Fischer A: The use of monoclonal antibodies in allogeneic bone marrow transplantation. Br J Haematol 83:531, 1993
35. Schlegel PG, Vaysburd M, Chen Y, Butcher EC, Chao NJ: Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol 155:3856, 1995
36. Haug CE, Colvin RB, Delmonico FL, Auchincloss H Jr, Tolkoff-Rubin N, Preffer FI, Rothlein R, Norris S, Scharschmidt L, Cosimi AB: A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 55:766, 1993
37. Archelos JJ, Jung S, Maurer M, Schmied M, Lassmann H, Tamatani T, Miyasaka M, Toyka KV, Hartung HP: Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 34:145, 1993
38. Gorcyznski RM, Chung S, Fu XM, Levy G, Sullivan B, Chen Z: Manipulation of skin graft rejection in alloimmune mice by anti-VCAM-1:VLA-4 but not anti-ICAM-1:LFA-1 monoclonal antibodies. Transplant Immunol 3:55, 1995
39. + anti-myelin basic protein rat T lymphocytes inhibit disease induction. J Immunol 147:1208, 1991
40. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL: Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA 89:421, 1992
41. + T cells from T cell receptor transgenic mice. J Exp Med 176:1091, 1992
42. Binder J, Hancock WW, Wasowska B, Gallon L, Watschinger B, Sayegh MH, Brock J, Lehmann M, Volk HD, Kupiec-Weglinski JW: Donor-specific transplantation unresponsiveness in sensitized rats following treatment with a nondepleting anti-CD4 MAb is associated with selective intragraft sparing of Th2-like cells. Transplant Proc 27:114, 1995
43. + T cells in the presence of a nondepleting monoclonal antibody to CD4 induces a Th2-type response in vitro. J Exp Med 182:5, 1995
44. Engelhardt B, Conley FK, Kilshaw PJ, Butcher EC: Lymphocytes infiltrating the CNS during inflammation display a distinctive phenotype and bind to VCAM-1 but not to MAdCAM-1 Int Immunol 7:481, 1995
45. Faveeuw C, Gagnerault MC, Lepault F: Expression of homing and adhesion molecules in infiltrated islets of Langerhans and salivary glands of nonobese diabetic mice. J Immunol 152:5969, 1994
46. Khoury SJ, Hancock WW, Weiner HL: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4 and prostaglandin E expression in the brain. J Exp Med 176:1355, 1992
47. Marini JC, Jameson BA, Lublin FD, Korngold R: A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis. J Immunol (in press)